Summary

• Novavax receives a Hold rating, reflecting neutral fundamentals despite a Q1 earnings beat and strong recent price momentum.
• NVAX's upside hinges on executing strategic partnerships, notably with Pfizer, and advancing its vaccine pipeline amid sector tailwinds from infectious disease outbreaks.
• Profitability remains elusive, with negative equity and choppy cash flow; consensus expects no positive EPS until at least 2028.
• Valuation implies nearly 40% upside to Wall Street's $14.11 target, but technicals and seasonal demand volatility temper conviction in a sustained rally.

A Vaccine Company With a Q1 Earnings Beat

After it beat Q1 earnings estimates by an impressive $0.31, Novavax (NVAX) gets initial coverage from me today in the biotech/pharma sector, whose profile describes it

1.76K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.